Market Closed -
Other stock markets
|
Pre-market 09:00:22 | |||
130.4 USD | +2.20% | 130.6 | +0.13% |
05-07 | CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab) | CI |
05-02 | Merck: encouraging results in gastric cancer | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.59% | 330B | |
+33.43% | 700B | |
-5.12% | 358B | |
+4.89% | 287B | |
+15.72% | 236B | |
+6.54% | 202B | |
-9.20% | 197B | |
+4.26% | 161B | |
-3.54% | 157B | |
+4.21% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135